Clinical Trial Update: Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy [Phase 4]

View source ↗

Summary

A Phase 4 randomized controlled trial studying the mechanistic effects of rifaximin in liver cirrhosis with hepatic encephalopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy
• Liver Cirrhosis

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: King's College Hospital NHS Trust | Conditions: Liver Cirrhosis, Hepatoencephalopathy, Early Fatal Progressive | Phase 4 | Status: COMPLETED